Medler Terry R, Blair Tiffany C, Crittenden Marka R, Gough Michael J
Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, United States.
Molecular Microbiology and Immunology, OHSU, Portland, OR, United States.
Front Oncol. 2021 Mar 19;11:667075. doi: 10.3389/fonc.2021.667075. eCollection 2021.
In the cancer literature tumors are inconsistently labeled as 'immunogenic', and experimental results are occasionally dismissed since they are only tested in known 'responsive' tumor models. The definition of immunogenicity has moved from its classical definition based on the rejection of secondary tumors to a more nebulous definition based on immune infiltrates and response to immunotherapy interventions. This review discusses the basis behind tumor immunogenicity and the variation between tumor models, then moves to discuss how these principles apply to the response to radiation therapy. In this way we can identify radioimmunogenic tumor models that are particularly responsive to immunotherapy only when combined with radiation, and identify the interventions that can convert unresponsive tumors so that they can also respond to these treatments.
在癌症文献中,肿瘤被不一致地标记为“免疫原性的”,并且实验结果偶尔会被忽视,因为它们仅在已知的“反应性”肿瘤模型中进行测试。免疫原性的定义已从基于继发性肿瘤排斥的经典定义转变为基于免疫浸润和对免疫治疗干预反应的更模糊定义。本综述讨论了肿瘤免疫原性背后的基础以及肿瘤模型之间的差异,然后转而讨论这些原理如何应用于对放射治疗的反应。通过这种方式,我们可以识别出仅在与放射联合时对免疫治疗特别敏感的放射免疫原性肿瘤模型,并确定能够使无反应性肿瘤发生转变从而也能对这些治疗产生反应的干预措施。